Bruce Maryanoff

Bruce Maryanoff is a R&D Advisor at DeuteRx. Bruce has over 45 years of experience in the pharmaceutical industry, starting their career in 1974 at McNeil Laboratories, Inc. Bruce then worked in McNeil Pharmaceutical (1979-1985), Janssen Research Foundation (1986-1989), and The R. W. Johnson Pharmaceutical Research Institute (RWJPRI; 1989-2001), all J&J subsidiaries. In 2001, they moved to Johnson & Johnson Pharmaceutical R&D (J&JPRD) [now part of Janssen Pharmaceutical Companies of Johnson & Johnson] where they conducted research until their retirement in 2010.

During their time in the pharmaceutical industry, Bruce Maryanoff invented topiramate, a blockbuster drug for treating epilepsy and migraine. Bruce also participated in the legal defense of a key composition-of-matter patent for topiramate, which received a favorable ruling in Federal Court.

After their retirement from J&JPRD, Bruce Maryanoff became an angel investor with Delaware Crossing Investment Group (DCIG). Bruce also served as a Distinguished Professor at the Baruch S. Blumberg Institute and as a Visiting Investigator at Scripps Research. In addition, they were a Professor of Chemical Biology at the Pennsylvania Drug Discovery Institute and an Associate Editor for ACS Medicinal Chemistry Letters from November 2009 to December 2020.

Bruce Maryanoff graduated from Princeton University with a B.S. in chemistry and then went on to earn their Ph.D. in organic chemistry from Drexel University.